Clinical trial
Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected…
NCT00002109 · Immunobiology Research Institute, Industry · Completed
Key facts
| NCT number | NCT00002109 |
|---|---|
| Title | Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy |
| Official title | Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT/ddI or AZT/ddC) Anti-Retroviral Therapy |
| Lead sponsor | Immunobiology Research Institute, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Thymopentin, Stavudine, Zidovudine, Zalcitabine, Didanosine |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: